This company has been marked as potentially delisted and may not be actively trading. Paratek Pharmaceuticals (PRTK) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PRTK Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Optinose CEO and other top executives exit after company's acquisition by ParatekMay 23, 2025 | bizjournals.comParatek expands commercial portfolio with OptinoseMay 22, 2025 | msn.comOptiNose Shareholders Approve Merger with ParatekMay 18, 2025 | investing.comParatek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International ConferenceMay 16, 2025 | globenewswire.comHow a Bucks County firm's multiyear pursuit of a partner led to a potential $330M dealApril 11, 2025 | bizjournals.comParatek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025April 10, 2025 | globenewswire.comParatek Pharmaceuticals to acquire Optinose in $330M transactionMarch 21, 2025 | markets.businessinsider.comOptinose Shares Surge Premarket on Takeover Deal With ParatekMarch 20, 2025 | marketwatch.comParatek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing CapabilitiesNovember 14, 2024 | globenewswire.comParatek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary DiseaseNovember 8, 2024 | globenewswire.comParatek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024October 14, 2024 | globenewswire.comParatek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated PathogensJuly 31, 2024 | globenewswire.comParatek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial PneumoniaJuly 18, 2024 | globenewswire.comParatek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPsMarch 5, 2024 | markets.businessinsider.comMira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and DatesFebruary 24, 2024 | benzinga.comParatek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023October 5, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 21, 2023 | finance.yahoo.comParatek Pharmaceuticals (Nasdaq:PRTK) HeadlineTrading was temporarily halted for "PRTK" at 07:09 PM with a stated reason of "News pending."...September 21, 2023 | marketbeat.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 19, 2023 | finance.yahoo.comParatek Pharmaceuticals shareholders approve $462M buyout dealSeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 18, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 12, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsSeptember 7, 2023 | finance.yahoo.comAcadian Asset Management LLC Sells 107,287 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)September 7, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 10, 2023 | benzinga.comHC Wainwright Comments on Paratek Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:PRTK)August 9, 2023 | marketbeat.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 7, 2023 | markets.businessinsider.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 4, 2023 | finance.yahoo.comCarlyle Group Inc. Takes Position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)August 4, 2023 | marketbeat.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionAugust 3, 2023 | finance.yahoo.comPRTK Paratek Pharmaceuticals, Inc.July 27, 2023 | seekingalpha.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | finance.yahoo.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 11, 2023 | msn.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | markets.businessinsider.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 10, 2023 | finance.yahoo.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16July 6, 2023 | msn.comParatek Pharmaceuticals (NASDAQ:PRTK) Earns Hold Rating from Analysts at StockNews.comJune 30, 2023 | marketbeat.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | msn.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalJune 27, 2023 | finance.yahoo.comEuropean Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals plans to go private in $462M dealJune 12, 2023 | bizjournals.comParatek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023June 12, 2023 | finance.yahoo.comPRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to ShareholdersJune 11, 2023 | businesswire.comThe Petri Dish: Startup chaired by Vertex founder raises $150M, Paratek to go private in $462M dealJune 8, 2023 | bizjournals.comJefferies Downgrades Paratek Pharmaceuticals (PRTK)June 7, 2023 | msn.comH.C. Wainwright downgrades Paratek Pharmaceuticals (PRTK) to a HoldJune 7, 2023 | markets.businessinsider.com Get Paratek Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTK Media Mentions By Week PRTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTK News Sentiment▼0.000.99▲Average Medical News Sentiment PRTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTK Articles This Week▼00▲PRTK Articles Average Week Get Paratek Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nektar Therapeutics News Today Omeros News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Pfizer News Today Bristol Myers Squibb News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTK Stock Alerts